Journal
MOLECULAR THERAPY
Volume 28, Issue 1, Pages 52-63Publisher
CELL PRESS
DOI: 10.1016/j.ymthe.2019.10.009
Keywords
-
Categories
Funding
- Jan Chorzempa Cancer Research Endowed Fund
- Masonic Cancer Center's Translational Working Group Grant
- Randy Shaver Cancer Research and Community Fund
- NIH/NCI [P30CA07759821, R21CA216652, U54CA232561]
- NCATS [UL1TR00249402]
- University of Minnesota Genomics Center
- Masonic Cancer Center
- Children's Cancer Research Fund
- Minnesota Supercomputing Institute
Ask authors/readers for more resources
Enhancing natural killer (NK) cell cytotoxicity by blocking inhibitory signaling could lead to improved NK-based cancer immunotherapy. Thus, we have developed a highly efficient method for editing the genome of human NK cells using CRISPR/Cas9 to knock out inhibitory signaling molecules. Our method efficiently edits up to 90% of primary peripheral blood NK cells. As a proof-of-principle we demonstrate highly efficient knockout of ADAM17 and PDCD1, genes that have a functional impact on NK cells, and demonstrate that these gene-edited NK cells have significantly improved activity, cytokine production, and cancer cell cytotoxicity. Furthermore, we were able to expand cells to clinically relevant numbers, without loss of activity. We also demonstrate that our CRISPR/Cas9 method can be used for efficient knockin of genes by delivering homologous recombination template DNA using recombinant adeno-associated virus serotype 6 (rAAV6). Our platform represents a feasible method for generating engineered primary NK cells as a universal therapeutic for cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available